Trinity Biotech
TRIB
28 hedge funds and large institutions have $16.6M invested in Trinity Biotech in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 7 closing their positions.
38% more call options, than puts
Call options by funds: $586K | Put options by funds: $426K
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
0% more ownership
Funds ownership: 0.04% → 0.05% (+0%)
13% less funds holding
Funds holding: 32 → 28 (-4)
18% less capital invested
Capital invested by funds: $20.3M → $16.6M (-$3.67M)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$1.37M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$282K |
| 3 |
LPL Financial
San Diego,
California
|
+$126K |
| 4 |
NA
Navellier & Associates
Reno,
Nevada
|
+$62.9K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$38.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$321K |
| 2 |
Millennium Management
New York
|
-$222K |
| 3 |
Squarepoint
New York
|
-$137K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$117K |
| 5 |
California Public Employees Retirement System
Sacramento,
California
|
-$106K |
TRIB Hedge Fund Activity: Q2 2021 in Review
28 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q2 2021, worth a combined $16.6M — down 18% from $20.3M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of TRIB and 3 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 8 added.
The largest buyer was Hunter Associates Investment Management, adding an estimated $1.37M. The largest seller was Morgan Stanley, cutting an estimated $321K.
- 28 institutional investors held Trinity Biotech (TRIB) as of Q2 2021, down from 32 in Q1 2021.
- Funds reported $16.6M of Trinity Biotech stock for Q2 2021, down 18% quarter-over-quarter.
- 3 funds opened new Trinity Biotech positions in Q2 2021 and 7 closed out, a net change of -4 holders.
- The largest Trinity Biotech buyer in Q2 2021 was Hunter Associates Investment Management, an estimated $1.37M added.
- The largest Trinity Biotech seller in Q2 2021 was Morgan Stanley, an estimated $321K sold.
Based on aggregated 13F filings for Q2 2021.